These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 22892289)

  • 1. Acute promyelocytic leukemia, centre, experience, Turkey.
    Yildirim R; Gundogdu M; Ozbıcer A; Kiki I; Erdem F; Dogan H
    Transfus Apher Sci; 2013 Feb; 48(1):45-9. PubMed ID: 22892289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute promyelocytic leukemia is a distinct subset of acute myelocytic leukemia with unique clinicopathologic characteristics including longer duration of relapse free survival: experience in 13 cases.
    Lee KH; Kim DH; Lee JS; Suh CW; Kim SW; Kim SB; Lee JH; Doh BS; Chi HS; Lee MS
    J Korean Med Sci; 1994 Dec; 9(6):437-43. PubMed ID: 7786438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
    Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
    Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia.
    Batzios C; Hayes LA; He SZ; Quach H; McQuilten ZK; Wall M; Campbell LJ
    Am J Hematol; 2009 Nov; 84(11):715-9. PubMed ID: 19806661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
    Callens C; Chevret S; Cayuela JM; Cassinat B; Raffoux E; de Botton S; Thomas X; Guerci A; Fegueux N; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Ferrand A; Sanz M; Chomienne C; Fenaux P; Dombret H;
    Leukemia; 2005 Jul; 19(7):1153-60. PubMed ID: 15889156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
    Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All-transretinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia.
    Al Bahar S; Pandita R; Bavishi K; Kreze O
    Indian J Cancer; 2004; 41(3):125-8. PubMed ID: 15472411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients.
    Liu YJ; Wu DP; Liang JY; Qiu HY; Jin ZM; Tang XW; Fu CC; Ma X
    Med Oncol; 2011 Dec; 28 Suppl 1():S513-21. PubMed ID: 21069477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.
    Lehmann S; Ravn A; Carlsson L; Antunovic P; Deneberg S; Möllgård L; Derolf AR; Stockelberg D; Tidefelt U; Wahlin A; Wennström L; Höglund M; Juliusson G
    Leukemia; 2011 Jul; 25(7):1128-34. PubMed ID: 21502956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience.
    Lobe I; Rigal-Huguet F; Vekhoff A; Desablens B; Bordessoule D; Mounier C; Ferrant A; Sanz M; Fey M; Chomienne C; Chevret S; Degos L; Fenaux P;
    Leukemia; 2003 Aug; 17(8):1600-4. PubMed ID: 12886249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.
    Kelaidi C; Chevret S; De Botton S; Raffoux E; Guerci A; Thomas X; Pigneux A; Lamy T; Rigal-Huguet F; Meyer-Monard S; Chevallier P; Maloisel F; Deconinck E; Ferrant A; Fegueux N; Ifrah N; Sanz M; Dombret H; Fenaux P; Adès L
    J Clin Oncol; 2009 Jun; 27(16):2668-76. PubMed ID: 19414681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience.
    Head DR; Kopecky KJ; Willman C; Appelbaum FR
    Leukemia; 1994; 8 Suppl 2():S38-41. PubMed ID: 7815835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute promyelocytic leukemia: an experience from a tertiary care centre in north India.
    Bajpai J; Sharma A; Kumar L; Dabkara D; Raina V; Kochupillai V; Kumar R
    Indian J Cancer; 2011; 48(3):316-22. PubMed ID: 21921331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
    Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
    Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of acute promyelocytic leukemia relapse in the ATRA era.
    Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
    Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
    Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
    J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
    Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
    Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.